Stockholm3 test (S3T)

Re: Wsparcie Mąż r.1952 PSA 20ng/ml BxGl.3+4cT2 HT IRE

Nieprzeczytany postautor: jesien 2015 » 28 lis 2018, 09:14

Informacja, ktora byc moze przyda sie komus, kto musi powtarzac biopsje, gdy pierwsza nie wykazala komorek nowotworowych. Generalnie tez, ktory pomaga okreslic czy pacjent moze byc poddany jedynie bacznej obserwacji czy leczenie powinno byc podjete natychmiast.

Test nie dotyczy pacjentow, u ktorych rak prostaty juz jest zdjagnozowany ani nie nadaje sie do monitorowania postepow leczenia.
Do tego w dalszym ciagu najlepsze jest monitorowanie PSA.
Do niedawna test byl dostepny jedynie w Szwecji, obecnie jeden z dunskich szpitali go wykonuje- probnie, z nadzieja, ze bedzie razem z PSA uzywany jako test przesiewowy. Testowany jest i w UK.
Test nazywa sie S3M ( popularnie test sztokhomski). Zapewne jest drogi dla osob spoza Szwecji, ale wiadomo, ze sa pacjenci, ktorzy sa w stanie zaplacic i miec pewnosc diagnozy. Nie jest to sprawidliwe jak wiele innych spraw w sluzbie zdrowia, ale mozliwosc istnieje. Nie jest to badanie komercyjne, prowadzone jest w osrodkach uniwersyteckich.

The Stockholm3 test, Sthlm3

https://sthlm3.se/stockholm3-in-english/
Maz rocznik 1952. Cukrzyca typ2. Niewielkie objawy powiększenia prostaty od końca września 2015
2015: X: PSA 20, XI: Biopsja: Gleason 7 (3+4), bez przejścia poza torebkę. W płacie prawym nie stwierdzono cech złośliwości. MR, PET/CT: PiRDAS 5, bez przejścia poza torebkę, naciek wzdłuż wiązki nerwowej, w prawym bez nacieku, węzły chłonne nie są powieszone, pojedyncze ognisko w okolicy iliac crest podejrzane o meta do kości.
2.XII rozpoczęto 16 dni Bicalutamide 50 mg 1 dziennie oraz jednocześnie Triptorelin (pamorelin) w zastrzyku co 6 miesięcy. Wznowienie metforminy. UniKalk ( Ca, wit D, wit K2). 19/12 Bicalutamide stop.
2016.02.09 Nanoknife. Po 14 dniach wyjecie cewnika, 100% trzymania moczu.
2016.03.05 Trzy miesiące od rozpoczęcia hormonoterapii: PSA 0,08 µg/L. Testosteron < 0,1nmol/L. Wit D 73 nmol/L ( norma >50 nmol/L)
2016.06.09 T 0,3 nmol/L, PSA < 0,06 µg/L Przerwa w HT na 4 miesiące.
2016.07.20 T 1,2 nmol/l, PSA nieoznaczalne. Nadal przerwa w HT.
2016.10.11 T 3,7 nmol/L, PSA nieoznaczalne. Nadal przerwa w HT.
2017.03.27 PSA nieoznaczalne, bez HT od 9 miesiecy
2017.09.27 PSA nieoznaczalne 2 lata od diagnozy, 20 miesiecy od IRE.
2018.10.05 PSA nieoznaczalne 3 lata od diagnozy, 2 lata i 8 miesiecy od IRE
------------ ----------------------------------------
" By kiedy przyjdzie pora na nie –
Na strach prawdziwy, gniew i rozpacz
Ujrzeć, że nie jesteśmy w stanie
Wielkim wyznaniom sprostać." Jacek Kaczmarski
jesien 2015
Użytkownik
 
Posty: 131
Rejestracja: 15 lis 2015, 10:32
Blog: Wyświetl blog (0)

Stockholm3 test (S3T)

Nieprzeczytany postautor: zosia bluszcz » 28 lis 2018, 11:13

Stockholm3 test

What is the Stockholm3 test?

The Stockholm3 test is a blood-based prostate cancer test that predicts the risk for aggressive prostate cancer[1] at biopsy by analyzing five protein markers[2], more than 100 genetic markers and clinical data[3]. The Stockholm3-test is available for clinical use in Sweden.

Background to the Stockholm3 test
Currently PSA is used to diagnose prostate cancer. However, the PSA-test cannot distinguish between aggressive and benign cancer and is often false positive. Therefore men who don’t have cancer, or have an indolent form of cancer that does not need treatment go through unnecessary and painful prostate biopsies. In addition, PSA misses many men with aggressive cancer and the result from a PSA test is often difficult for the treating doctor to interpret.

Advantages with the Stockholm3 test compared to current clinical practice
Increases the detection of aggressive cancers and reduces the number of men that need to undergo unnecessary biopsies. The Stockholm3 test finds 20% more aggressive cancers and reduces the number of unnecessary biopsies by 50% compared to clinical practice[4].
Finds aggressive cancer in men with low PSA-values. The Stockholm3 test can find aggressive cancer in men with PSA levels of 1-3 ng/ml. This is cancer that often goes undetected today. In the age range 50-70 years, four men out of ten have a PSA between 1-3 ng/ml[5].
Provides an answer with a clear and easy-to-interpret recommendation. The Stockholm3 test provides a clear and easy-to-interpret recommendation. This makes it easier for the treating doctor to make a decision on potential further actions. It also helps the man to get a better understanding of his individual risk of getting prostate cancer. For example, nearly half of the men aged 50-70 years have a very low risk profile and do not need to take a new test until after 6-10 years.
Evaluation of the Stockholm3 test

The Stockholm3 test was evaluated in the STHLM3 trial with nearly 60,000 men from Sweden that was carried out by researchers at Karolinska Institutet in 2012-2015.

Interpretation of the answer from the Stockholm3 test
The result from the Stockholm3 test consists of an answer and a easy-to-interpret recommendation. The answer from the Stockholm3 test can be negative or positive. If negative, the man has a low or normal risk for prostate cancer with recommended follow-up in 6-10 years respective 2-4 years. If the answer is positive the man is recommended to be referred to a urologist. Depending on risk level a prostate volume cut-off is set. A urologist measures the prostate volume and conducts a digital rectal exam. If the prostate volume is smaller than the cut-off and or the digital rectal exam is positive a biopsy is recommended. Otherwise a new Stockholm3 test is recommended in 2 years.

Who should not take the Stockholm3 test?
The Stockholm3 test has no proven value for men with a known prostate cancer. The value of taking the test for men who have recently been through biopsy and evaluation with urologist can be discussed. The Stockholm3 test should not be taken on men who are being followed up after a previous prostate cancer. The Stockholm3 test does not replace biopsy for men on active monitoring. The Stockholm3 test has not been evaluated on men below 50 year or men above 70 years. There is no scientific evidence that it is of any benefit to find prostate cancer in men above 75 years old.


Further research
In the “STHLM3 MRI/Fusion” study the Stockholm3 test is combined with magnetic resonance imaging scans to further improve the identification of aggressive prostate cancer. The study is ongoing and applicable clinical results are expected in Q4 2017. In a study funded by Prostate Cancer UK the Stockholm3 test will be evaluated in the British health care system and in different ethnicities. The study will start in 2017.

Availability of the Stockholm3 test outside of Sweden
The Stockholm3 test in not yet available outside of Sweden. If you would like to take the Stockholm3 test you could contact any of the following clinics:

Executive Health. Phone +46 8 4109 5700 or Executive Health.
Urologi STHLM. Phone +46 8 5871 0310 or Urologi STHLM.
Nackahälsan. Phone +46 8 716 9420 or NackaHälsan.


_________________
[1] Defined as Gleason Score≥7

[2] Total PSA, free PSA, HK2, MSMB and MIC1

[3] Age, earlier prostate biopsy, family history of prostate biopsy and use of 5-alfareducase inhibitors. In addition digital rectal examination (DRE) and prostate volume is used on men referred to urologist

[4] European Urology Focus, 2016. In press.

[5] The Lancet Oncology, 2015


https://sthlm3.se/stockholm3-in-english/
[color=#FFBF00]..........................Obrazek
zosia bluszcz
Złoty Gladiator
Złoty Gladiator
 
Posty: 7848
Rejestracja: 13 cze 2009, 00:06
Blog: Wyświetl blog (0)


Wróć do O czym powinniśmy wiedzieć przed, w trakcie, po leczeniu

Kto jest online

Użytkownicy przeglądający to forum: Obecnie na forum nie ma żadnego zarejestrowanego użytkownika i 4 gości

logo zenbox